

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 January 2025 (30.01.2025)



(10) International Publication Number
WO 2025/021916 A1

(51) International Patent Classification:

A61K 9/00 (2006.01) *A61K 47/18* (2017.01)
A61K 9/08 (2006.01) *A61K 47/26* (2006.01)
A61K 38/18 (2006.01) *A61K 47/34* (2017.01)
A61K 47/02 (2006.01)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(21) International Application Number:

PCT/EP2024/071109

(22) International Filing Date:

25 July 2024 (25.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23188159.0 27 July 2023 (27.07.2023) EP

(71) Applicant: **DOMPE' FARMACEUTICI S.P.A.** [IT/IT];
Via San Martino, 12, 20122 Milano (IT).

(72) Inventors: **MATTIOLI, Simone**; 67100 L'Aquila (IT).
DETTA, Nicola; C/O DOMPE' FARMACEUTICI SPA,
Via Pietro Castellino, 111, 80131 Napoli (IT). **APPAR-
ENTE, Lucia**; Via Campo di Pile, 67100 L'Aquila (IT).
ROMEO, Tiziana; C/O Dompé farmaceutici Spa, Via
Campo di Pile, 67100 L'Aquila (IT).

(74) Agent: **MAURI, Elisabetta Maria Ester**; C/O DOMPE'
FARMACEUTICI SPA, VIA SANTA LUCIA 6, 20121
MILANO (IT).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: PHARMACEUTICAL FORMULATION COMPRISING NERVE GROWTH FACTOR

(57) Abstract: A liquid pharmaceutical formulation, suitable for lyophilization, comprising nerve growth factor (NGF) and at least one pharmaceutically acceptable excipient.

WO 2025/021916 A1